Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Announces Quarterly Earnings Results

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) announced its quarterly earnings data on Wednesday. The company reported $1.08 EPS for the quarter, Zacks reports. Recordati Industria Chimica E Farmaceutica had a net margin of 16.92% and a return on equity of 34.11%.

Recordati Industria Chimica E Farmaceutica Price Performance

OTCMKTS RCDTF remained flat at $55.88 during trading hours on Wednesday. Recordati Industria Chimica E Farmaceutica has a 52-week low of $55.88 and a 52-week high of $56.95. The business’s 50 day moving average is $56.74 and its two-hundred day moving average is $62.20. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.64 and a quick ratio of 1.16. The firm has a market cap of $11.53 billion, a PE ratio of 23.35 and a beta of 0.23.

Wall Street Analysts Forecast Growth

RCDTF has been the topic of several analyst reports. Kepler Capital Markets upgraded shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 3rd. Barclays raised shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy?based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family?owned enterprise in Milan.